Abstract
The administration of adriamycin to rates increased (P less than 0.01) the interval, measured in msec, of the electrocardiographic QRS traces in rats, and the magnitude of the increase was ca. 50%. The administration of coenzyme Q10 to such adriamycin-treated rats allowed "rescue" or restoration of a normal QRS complex after 7 days of administration of coenzyme Q10. The QRS complex then remained normalized during the subsequent period of 21-30 days, by which time the cumulative dose of adriamycin had reached 24 mg/kg. Also, the QRS interval was lower (P less than 0.01) on day 33 than it was for rats treated to the same day with adriamycin alone. Coenzyme Q10 offers promise of rescue from at least some of the cardiotoxicity occurring in adriamycin-treated cancer patients, probably by a similar mechanism to that of the clinical rescue from toxicity of methotrexate by a cofactor of folic acid (citrovorum factor).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bertazzoli C., Ghione M. Adriamycin associated cardiotoxicity: research on prevention with coenzyme Q. Pharmacol Res Commun. 1977 Mar;9(3):235–250. doi: 10.1016/s0031-6989(77)80073-8. [DOI] [PubMed] [Google Scholar]
- Combs A. B., Choe J. Y., Truong D. H., Folkers K. Reduction by coenzyme Q10 of the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol. 1977 Nov;18(3):565–568. [PubMed] [Google Scholar]
- Folkers K. The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2. 1974 Dec;4(4):19–22. [PubMed] [Google Scholar]
- Frei E., 3rd, Jaffe N., Tattersall M. H., Pitman S., Parker L. New approaches to cancer chemotherapy with methotrexate. N Engl J Med. 1975 Apr 17;292(16):846–851. doi: 10.1056/NEJM197504172921607. [DOI] [PubMed] [Google Scholar]
- Iwamoto Y., Hansen I. L., Porter T. H., Folkers K. Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun. 1974 Jun 4;58(3):633–638. doi: 10.1016/s0006-291x(74)80465-1. [DOI] [PubMed] [Google Scholar]
- Jaenke R. S. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 1974 Mar;30(3):292–304. [PubMed] [Google Scholar]
- Kishi T., Folkers K. Letter: Prevention by coenzyme Q10 (NSC-140865) of the inhibition by adriamycin (NSC-123127) of coenzyme Q10 enzymes. Cancer Treat Rep. 1976 Mar;60(3):223–4?U9ENG. [PubMed] [Google Scholar]
- Kishi T., Watanabe T., Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. Proc Natl Acad Sci U S A. 1976 Dec;73(12):4653–4656. doi: 10.1073/pnas.73.12.4653. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lenaz L., Page J. A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev. 1976 Sep;3(3):111–120. doi: 10.1016/s0305-7372(76)80018-7. [DOI] [PubMed] [Google Scholar]
- Mettler F. P., Young D. M., Ward J. M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977 Aug;37(8 Pt 1):2705–2713. [PubMed] [Google Scholar]
- Zbinden G., Brändle E. Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats. Cancer Chemother Rep. 1975 Jul-Aug;59(4):707–715. [PubMed] [Google Scholar]